On August 3, 2011, the Food and Drug Administration issued a Drug Safety Communication informing the public that chronic, high doses (400-800 mg\/day) of the antifungal drug Diflucan, active ingredient fluconazole, may be associated with a rare and distinct set of birth defects in infants whose mothers were treated with the drug during the first trimester of pregnancy.<\/p>\n","protected":false},"excerpt":{"rendered":"
On August 3, 2011, the Food and Drug Administration issued a Drug Safety Communication informing the public that chronic, high doses (400-800 mg\/day) of the antifungal drug Diflucan, active ingredient fluconazole, may be associated with a rare and distinct set of birth defects in infants whose mothers were treated with the drug during the first … Continue reading FDA Drug Safety Podcast for Healthcare Professionals: Use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants<\/span>